Patent: 10,052,345
✉ Email this page to a colleague
Summary for Patent: 10,052,345
Title: | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
Abstract: | Assays, methods and kits for predicting a subject\'s (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders. |
Inventor(s): | Fornoni; Alessia (Coral Gables, FL), Burke; George William (Miami, FL), Merscher-Gomez; Sandra (Miami, FL) |
Assignee: | University of Miami (Miami, FL) |
Application Number: | 13/879,892 |
Patent Claims: | see list of patent claims |
Details for Patent 10,052,345
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | 12/23/2005 | ⤷ Try a Trial | 2030-10-19 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 07/29/2011 | ⤷ Try a Trial | 2030-10-19 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 06/07/2016 | ⤷ Try a Trial | 2030-10-19 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 03/30/2017 | ⤷ Try a Trial | 2030-10-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |